Abstracts tagged "Lupus"

Abstract Number: 2100 • 2018 ACR/ARHP Annual Meeting
Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus
Samantha Chalmers¹, Sayra Garcia¹, Andrew Draganski¹, Jessica Doerner², Adam Friedman³, Joel Friedman¹ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Pennsylvania, Philadelphia, PA, ³Dermatology, GW School of Medicine and Health Sciences, Washington, DC, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Cutaneous lupus erythematosus (CLE) affects ~75% of SLE patients and has a profound impact on quality of life. While the morbidity from CLE is…
Abstract Number: 2796 • 2018 ACR/ARHP Annual Meeting
Sex-Based Differences Control ABC Function in Swef-Deficient Mice
Michela Manni¹, Danny Flores-Castro², Chao Ye², Edd Ricker¹, Sanjay Gupta³, Yurii Chinenov⁴, Tania Pannellini² and Alessandra B. Pernis⁵, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ⁴Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁵David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Age-associated B cells (ABCs) are a novel B cell subset, which expands with age in non-autoimmune mice but accumulates prematurely in autoimmune-prone strains. ABCs…
Abstract Number: 459 • 2018 ACR/ARHP Annual Meeting
Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Angel Alberto Herrera Guerra¹, Sampath Prahalad¹, Kelly A. Rouster-Stevens¹, Rouba Garro², Leah Bryan³ and Yin Hong⁴, ¹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Pediatric Nephrology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pathology, Children's Health Care of Atlanta, Atlanta, GA
Background/Purpose: There is a paucity of data regarding the early hospital readmission rates in newly diagnosed childhood lupus nephritis (cLN). We conducted a retrospective study…
Abstract Number: 748 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
Lara Sánchez-Bilbao¹, Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Marina de Cos-Gómez², Íñigo González-Mazón¹, Diana Prieto Peña³, Monica Calderón Goercke³, Juan Carlos Ruiz San Millán², Emilio Rodrigo Calabia², Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, affecting up to 40% of patients. Unfortunately, about 20% of LN develop end…
Abstract Number: 1707 • 2018 ACR/ARHP Annual Meeting
Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive Patients
Olga Vera-Lastra¹, Cristopher Vázquez², María Pilar Cruz-Dominguez³ and Luis J. Jara-Quezada⁴, ¹Internal Medicine, Hospital de Especialidades Centro Medico nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ²Internal medicine Department, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ³Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional "La Raza", Mexico City, Mexico, ⁴Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional,, Mexico, Mexico
Background/Purpose: Prolactin has a role in pathogenesis of Systemic Lupus Erythematous (SLE); high levels have been associated with activity. In contrast, a decrease in dehydroepiandrosterone…
Abstract Number: 2114 • 2018 ACR/ARHP Annual Meeting
Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes
Grace Hile¹, Mrinal Sarkar², Jianhua Liu³, Tamra J. Reed⁴, Johann Gudjonsson² and Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²Dermatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Photosensitivity, defined as increased cutaneous erythema and inflammation after ultraviolet light (UV) exposure, is a hallmark of patients with systemic lupus erythematosus (SLE), cutaneous…
Abstract Number: 2807 • 2018 ACR/ARHP Annual Meeting
Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
Candace H. Feldman¹, Susan Malspeis², Cianna Leatherwood¹, Laura Kubzansky³, Karen Costenbader¹ and Andrea Roberts⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁴Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Prior studies demonstrated associations between post-traumatic stress disorder and increased risk of incident SLE and between childhood trauma and increased risk of hospitalization for…
Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Anna Carmela Sagcal-Gironella¹, Eyal Muscal², Andrea A. Ramirez¹, Monica Marcus³, Miriah Gillispie¹, William Blaine Lapin¹ and Marietta M. De Guzman⁴, ¹Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, ³Deaprtment of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…
Abstract Number: 750 • 2018 ACR/ARHP Annual Meeting
Positive Remodeling Index and Low Attenuation Non-Calcified Coronary Plaques: Markers of Vulnerable Coronary Plaques in Systemic Lupus?
George Stojan¹, Laurence Magder² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Department of Epidemiology, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. Positive remodeling index and presence of low…
Abstract Number: 1709 • 2018 ACR/ARHP Annual Meeting
Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
Lindsey Warner and Shazia Beg, University of Central Florida College of Medicine, Orlando, FL
Background/Purpose: Lupus is an autoimmune disease with multitude of symptoms that are often not fully controlled by standard biomedical treatments. This study was designed to…
Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Giuseppe Alvise Ramirez^1,2,3,4, Hannah Cohen^5,6, David A. Isenberg^4,7 and Maria Efthymiou⁵, ¹Università Vita-Salute San Raffaele, Milan, Italy, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁵Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ⁶Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…
Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Rosalind Ramsey-Goldman¹, Roberta Alexander², Elena Massarotti³, Daniel J. Wallace⁴, Sonali Narain⁵, Cristina Arriens⁶, Christopher E. Collins⁷, Amit Saxena⁸, Chaim Putterman⁹, Kenneth C. Kalunian¹⁰, Armida Sace², Rowena Lafon², Tyler O'Malley², JoAnne Ligayon², Claudia Ibarra², John Conklin², Thierry Dervieux² and Arthur Weinstein⁷, ¹FSM, Northwestern University, Chicago, IL, ²Exagen Diagnostics, Inc., Vista, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Northwell Health, Great Neck, NY, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ⁸NYU Langone Health, New York, NY, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…
Abstract Number: 466 • 2018 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
Saimun Singla and Marietta M. De Guzman, Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Streptococcus pneumonia is a leading cause of illness in children worldwide and can lead to death in those with an immunosuppressed status. Given the…
Abstract Number: 751 • 2018 ACR/ARHP Annual Meeting
Coronary Plaque Burden in Patients with Lupus Compared to Healthy Volunteers
George Stojan¹, Matthew Budoff², Laurence Magder³, Jessica Li⁴, Armin Zadeh⁵, Erik Barr⁶ and Michelle Petri⁵, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ³Department of Epidemiology, University of Maryland, Baltimore, MD, ⁴Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. We sought to characterize noncalcified and calcified…
Abstract Number: 1714 • 2018 ACR/ARHP Annual Meeting
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, R. Paola Daly¹, Leslie Hanrahan², Annick Anderson³, Kathleen Arntsen⁴, Sang-Cheol Bae⁵, Ian N. Bruce⁶, Karen Costenbader⁷, Thomas Dörner⁸, Amy H. Kao⁹, Susan Manzi¹⁰, Eric Morand¹¹, Sandra Raymond¹, Brad H. Rovin¹², Laura E. Schanberg¹³, Victoria P. Werth¹⁴, Joan Von Feldt¹⁵ and Kenneth Getz³, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Washington DC, DC, ³Tufts Center for the Study of Drug Development, Boston, MA, ⁴Lupus and Allied Diseases, Inc., Verona, NY, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹⁰Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ¹¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹²Ohio State University Medical Center, Columbus, OH, ¹³Duke University Medical Center, Durham, NC, ¹⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁵GlaxoSmithKline, Philadelphia, PA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus initiative seeking to identify and prioritize top barriers in lupus impacting…

« Previous Page
1
…
6
7
8
9
10
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].